August 16, 2021 10:28 AM EDT

Boehringer Ingelheim scraps $600M+ lung cancer program with CureVac, as the biotech preps its second Covid-19 shot

Max Gelman

Senior Editor

The German biotech CureVac released its second quarter update Monday morning, and disclosed among the Covid-19 vaccine highlights that a $600 million-plus oncology partnership with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Boehringer Ingelheim scraps $600M+ lung cancer program with CureVac, as the biotech preps its second Covid-19 shot

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Minnesota 340B revenue driven by hospitals and high-priced drugs, first state report says

Boehringer In­gel­heim scraps $600M+ lung can­cer pro­gram with Cure­Vac, as the biotech preps its sec­ond Covid-19 shot

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Min­neso­ta 340B rev­enue dri­ven by hos­pi­tals and high-priced drugs, first state re­port says

Boehringer Ingelheim scraps $600M+ lung cancer program with CureVac, as the biotech preps its second Covid-19 shot

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Minnesota 340B revenue driven by hospitals and high-priced drugs, first state report says